Daewoong Pharmaceutical Co Ltd 069620
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- ₩135,500.00
- Day Range
- ₩136,000.00–142,200.00
- 52-Week Range
- ₩97,400.00–152,000.00
- Bid/Ask
- ₩139,500.00 / ₩140,000.00
- Market Cap
- ₩1.61 Tril
- Volume/Avg
- 27,628 / 74,713
Key Statistics
- Price/Earnings (Normalized)
- 18.05
- Price/Sales
- 1.14
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,770
- Website
- https://www.daewoong.co.kr
Comparables
Valuation
|
Metric
|
069620
|
019170
|
140410
|
|---|---|---|---|
Price/Earnings (Normalized) | 18.05 | — | — |
Price/Book Value | 2.09 | 2.34 | 19.33 |
Price/Sales | 1.14 | 2.98 | 40.42 |
Price/Cash Flow | 11.40 | — | — |
Price/Earnings
069620
019170
140410
Financial Strength
|
Metric
|
069620
|
019170
|
140410
|
|---|---|---|---|
Quick Ratio | 0.53 | 1.99 | 2.03 |
Current Ratio | 0.96 | 2.80 | 2.65 |
Interest Coverage | 14.37 | −15.46 | −29.56 |
Quick Ratio
069620
019170
140410
Profitability
|
Metric
|
069620
|
019170
|
140410
|
|---|---|---|---|
Return on Assets (Normalized) | 6.29% | −11.95% | −13.89% |
Return on Equity (Normalized) | 14.97% | −15.05% | −23.04% |
Return on Invested Capital (Normalized) | 8.46% | −12.71% | −20.98% |
Return on Assets
069620
019170
140410
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Lysxmvcy | Zpn | $86.1 Bil | |||
| Merck KGaA ADR
MKKGY
| Lfqffyfl | Lrptb | $74.3 Bil | |||
| Haleon PLC ADR
HLN
| Hnxqftzb | Rkmkz | $45.9 Bil | |||
| Viatris Inc
VTRS
| Bhjcsyn | Nkvz | $13.8 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Btqrtncr | Ywnw | $13.2 Bil | |||
| Catalent Inc
CTLT
| Hfkxmfqp | Vblmmp | $11.0 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Sklkdphsj | Vsdmxb | $3.4 Bil | |||
| Perrigo Co PLC
PRGO
| Clyvjcqm | Hdxsl | $3.4 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Pyvjgrrr | Yktv | $2.4 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Vkjkdtpq | Ppdbl | $2.2 Bil |
United States